Aarti Drugs climbs 3% on its assessments to stay clear of Covid-19 impact

The operations at the company’s manufacturing facilities continued except for the period starting from March 24-29, 2020.

Jul 06, 2020 01:07 IST India Infoline News Service

Aarti Drugs
Aarti Drugs Limited updated the exchanges Friday that there may not be any material impact on the operations of the company in future due to Covid-19. There is likely to be no impact on the capital and financial resources, profitability and liquidity position of the company.

The stock is currently trading at Rs1,311.95 up by Rs38.4 or 3.02% from its previous closing of Rs1,273.55 on the BSE.

"Healthcare Industry being into essential services has not been impacted by countrywide lockdown adversely. The operations at the company’s manufacturing facilities continued except for the period starting from March 24-29, 2020 when a majority of the employees could not reach to factory location because of restriction on the movement of manpower, unavailability of transportation etc. Subsequently, based on its product profile, the company was granted permissions to operate our manufacturing facilities, movement of critical workforce, materials, etc", informed the company.

"Due to scarcity of logistics facility supply of raw material and dispatches of finished goods were affected at initial stage of lockdown which has now improved and clocked close to normalcies. From the time of commencement of lockdown, the company has provided the Work from Home facility to employees of Mumbai Head office with necessary connectivity. All IT Security Protocols are in place and all systems are being monitored remotely".

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity